May 2003
Volume 44, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2003
Glaucoma as a Possible Factor for Vision Loss in the TTT4CNV Clinical Trial
E. Reichel; D.C. Musch; M.W. Johnson; D.J. D'Amico; T.R. Friberg; R. Landis; M.A. Mainster
Author Affiliations & Notes
  • E. Reichel
    Ophthal-Tufts Univ Sch of Med, New England Eye Center, Boston, MA, United States
  • D.C. Musch
    Ophthalmology, University of Michigan, Ann Arbor, MI, United States
  • M.W. Johnson
    Ophthalmology, University of Michigan, Ann Arbor, MI, United States
  • D.J. D'Amico
    Ophthalmology, Massachusetts Eye and Ear Infirmary, Boston, MA, United States
  • T.R. Friberg
    Ophthalmology, University of Pittsburgh, Pittsburgh, PA, United States
  • R. Landis
    University of Pennsylvania, Philadelphia, PA, United States
  • M.A. Mainster
    Ophthalmology, University of Kansas, Kansas City, KS, United States
  • Footnotes
    Commercial Relationships  E. Reichel, Iridex C, R; D.C. Musch, None; M.W. Johnson, None; D.J. D'Amico, None; T.R. Friberg, Iridex F; R. Landis, None; M.A. Mainster, Iridex C.
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 5043. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Glaucoma as a Possible Factor for Vision Loss in the TTT4CNV Clinical Trial
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      E. Reichel, D.C. Musch, M.W. Johnson, D.J. D'Amico, T.R. Friberg, R. Landis, M.A. Mainster; Glaucoma as a Possible Factor for Vision Loss in the TTT4CNV Clinical Trial . Invest. Ophthalmol. Vis. Sci. 2003;44(13):5043.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Abstract: : Purpose: The TTT4CNV Clinical Trial is a study designed to determine if transpupillary thermotherapy (TTT) is effective in preventing further visual loss from occult choroidal neovascularization (CNV) associated with age-related macular degeneration. Methods: A randomized, sham-controlled, multi-centered study. Results: A review of over 280 patients enrolled in the TTT4CNV Clinical Trial revealed that 7 (2.5%) patients were reported to have loss of vision immediately after TTT. Of these 7 patients, 3 (42.9%) had pre-existing glaucoma, whereas the frequency of pre-existing glaucoma among patients receiving TTT who did not experience visual loss was 4.8% (7/147). This significant association [odds ratio, 15.0 (95% CI,2.8,80.4);P=0.006, Fisher's exact test],albeit based on a small number of patients, led the study's Data and Safety Monitoring Committee to advise adding pre-existing glaucoma as an exclusion criterion for further enrollment. Conclusions: Possible reasons why glaucoma could contribute to a higher risk of acute, severe vision loss upon being treated with TTT and considerations for the management of these patients will be discussed.

Keywords: age-related macular degeneration • laser • clinical (human) or epidemiologic studies: tre 
© 2003, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2025 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept